Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection. Issue 2 (7th February 2023)

• Record Type: Journal Article
• Authors: Chen, Zehui; Li, Jiaming; Zheng, Jing; Jin, Yifei; Zhang, Yidun; Tang, Fei; Li, Jingjing; Cheng, Hongliang; Jiang, Lina; Wen, Huixin; Hong, Chao; Zeng, Xiaohong; Huang, Shijie; Lu, Bing; Li, Li; Wang, Zhongyi
• Is Part Of: Journal of medical virology. Volume 95:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2023-02-07
• Subjects: human infection -- neutralizing immunity evasion -- Omicron subvariants; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28539
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: The newly emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron BA.2.75 and BA.2.76 subvariants contained 35 and 29 additional mutations in its spike (S) protein compared with the reference SARS‐CoV‐2 genome, respectively. Here, we measured the evasion degree of the BA.1, BA.2, BA.4, BA.5, BA.2.75, and BA.2.76 subvariants from neutralizing immunity in people previously infected with the Omicron BA.1 and BA.2, determined the effect of vaccination on immune evasion, and compared the titers of neutralizing antibodies in serums between acute infection and convalescence. Results showed that the neutralization effect of serums from patients with different vaccination statuses and BA.1/BA.2 breakthrough infection decreased with the Omicron evolution from BA.1 to BA.2, BA.4, BA.5, BA.2.75, and BA.2.76. This study also indicated that the existing vaccines could no longer provide effective protection, especially for the emerging BA.2.75 and BA.2.76 subvariants. Therefore, vaccines against emerging epidemic strains should be designed specifically. In the future, we can not only focus on the current strains, but also predict and design new vaccines against potential mutant strains. At the same time, we can combine the virus strains' infection characteristics to develop protective measures for virus colonization areas, such as nasal protection spray. Besides, further studies on the Y248N mutation of BA.2.76 subvariant were also necessary to explore its contribution to the enhanced immune evasion ability.